Core Points - On November 19, 2025, Sinovac Biotech (SVA.NASDAQ) announced it received a delisting notice from the NASDAQ Stock Market due to failure to submit its 2024 annual report by the extended deadline of November 11, 2025 [2] - If Sinovac does not timely request a hearing from the NASDAQ Hearing Committee, its securities will be suspended from trading and delisted on November 21, 2025 [2] - Sinovac stated it has engaged UHY LLP as an independent auditing firm and is actively cooperating to expedite the annual report audit and preparation [2] - The company is in ongoing communication with NASDAQ and plans to request an extension for the annual report submission and a hearing regarding the delisting matter [2] - Sinovac emphasized that its U.S. listing status will not materially affect its core business operations, and all vaccine research, production, supply, and marketing activities are proceeding normally [2] - As of the suspension date, Sinovac's total market capitalization was approximately $389 million [2]
科兴生物(SVA)，收到纳斯达克退市通知